Format

Send to

Choose Destination
Anticancer Res. 2015 Dec;35(12):6941-50.

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.

Author information

1
Hospital 12 de Octubre, ONCOSUR, Madrid, Spain lmanso@salud.madrid.org.
2
Hospital de León, León, Spain.
3
Clínica Quirón Madrid, Madrid, Spain.
4
Hospital de Guadalajara, ONCOSUR, Guadalajara, Spain.
5
Hospital General de Segovia, ONCOSUR, Segovia, Spain.
6
Hospital Virgen de la Salud, ONCOSUR, Toledo, Spain.
7
Hospital de Alcorcón, ONCOSUR, Madrid, Spain.
8
Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
9
Hospital de Elda, Alicante, Spain.
10
Hospital Clinic i Provincial, Barcelona, Spain.
11
Hospital Dr. Peset, Valencia, Spain.
12
Hospital de Luis Alcanyis, Xátiva, Valencia, Spain.
13
Hospital General San Jorge, Huesca, Spain.
14
Hospital de Basurto, Vizcaya, Spain.
15
Hospital Infanta Cristina, ONCOSUR, Madrid, Spain.
16
Hospital Son Llatzer, Palma de Mallorca, Spain.
17
Hospital General de Ciudad Real, ONCOSUR, Ciudad Real, Spain.
18
Hospital San Pedro de Alcántara, ONCOSUR, Cáceres, Spain.
19
Hospital Universitario La Princesa, Madrid, Spain.
20
Hospital Infanta Cristina, ONCOSUR, Badajoz, Spain.
21
Hospital de Sagunto, Valencia, Spain.
22
Hospital Mutua de Terrassa, Barcelona, Spain.
23
Hospital Son Dureta, Palma de Mallorca, Spain.
24
Hospital 12 de Octubre, ONCOSUR, Madrid, Spain.

Abstract

AIM:

To evaluate factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer (MBC) in clinical practice in Spain.

PATIENTS AND METHODS:

All consecutive adult female patients with HER2-negative MBC who had received first-line bevacizumab plus chemotherapy for at least 3 months were enrolled in the present study.

RESULTS:

A total of 292 evaluable patients were included; 25% had triple-negative breast cancer (TNBC) and 75% had hormone receptor-positive breast cancer (HRPBC). Nearly 40% of patients had ≥3 metastatic sites, mainly located in the bone (48%) and liver (40%). Bevacizumab was mostly combined with paclitaxel (67.1%). ER-positive tumors were only identified as an independent factor associated with the choice of treatment (odds ratio (OR): 0.538; p=0.02). The overall response rate (ORR) was 63.7% (TNBC: 57.5%; HRPBC: 65.9%). Patients aged 36-50 years (OR: 3.03; p=0.028) and those with metastases at sites other than the bone (OR: 0.38; p=0.001) and ≥3 metastatic sites (OR: 1.41; p=0.018) were more likely to achieve objective responses.

CONCLUSION:

First-line bevacizumab plus chemotherapy, mainly paclitaxel, is an effective and well-tolerated treatment option for HER2-negative MBC, particularly in more aggressive disease.

KEYWORDS:

Bevacizumab; breast cancer; epidermal growth factor receptor (HER2)-negative; metastatic disease; predictive factors

PMID:
26637920
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center